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Abstract 212 words 
Carbon nanotubes are appealing imaging and therapeutic systems. Their structure allows 
not only a useful display of molecules on their outer surface but at the same time the 
protection of encapsulated cargoes. Despite the interest they have provoked in the scientific 
community their applications have not yet been fully realised due to the limited knowledge 
we possess concerning their physiological behaviour. Previously, we have shown that the 
encapsulation of radionuclide in the inner space of glycan-functionalized single-walled 
carbon nanotubes (glyco-X@SWCNT) redirected in vivo distribution of radioactivity from the 
thyroid to the lungs. Here we test the roles played by such glycans attached to carbon 
nanotubes in controlling sites of accumulation using nanotubes carrying both ‘cold’ and ‘hot’ 
salt cargoes decorated with two different mammalian carbohydrates, N-acetyl-D-
glucosamine (GlcNAc) or galactose(Gal)-capped disaccharide lactose (Gal–Glc). This 
distinct variation of the terminal glycan displayed between two types of glycan ligands with 
very different in vivo receptors, coupled with altered sites of administration, suggest that 
distribution in mammals is likely controlled by physiological mechanisms that may include 
accumulation in the first capillary bed they encounter and not by glycan-receptor interaction 
and that the primary role of glycan is in aiding the dispersibility of the CNTs. 
 
 




The inner cavities of carbon nanotubes (CNTs) can accommodate a wide range of 
guest species [1-4]. Unprecedented structures and properties compared to those of the 
same material in the bulk can be observed when they are confined [5-11]. In the 
biomedical field, contrast agents and therapeutic compounds can be either attached to 
the external CNT walls or confined within the cavities of the CNTs [12-18]. The latter is 
attractive because CNTs can offer striking protection to chosen payloads avoiding their 
interaction with the biological milieu [19].  
Several strategies have been developed for the encapsulation of materials inside 
carbon nanotubes. Once filled, unless there is a strong interaction between the host 
nanotubes and the guest species, the ends of the CNTs need to be sealed/closed to 
allow selective purification from non-encapsulated materials left external to the CNT. 
Heating nanotubes together with inorganic salts at high temperatures allows capillary 
permeation of the melted salts inside the nanotubes with the spontaneous closure of 
the extremities during the cooling process [20, 21]. The salts remain stably confined in 
the form of ‘nanocrystals’ inside the nanotubes while leaving the outer surface 
unaffected, and so ready to be modified by organic molecules.  
As-produced, CNTs are insoluble in almost any aqueous solution and organic solvent, 
and have been suggested to be toxic to mammalian cells [22], thereby presenting 
perceived limitations to their biological applications [23-27]. Functionalization of CNT 
side-walls with biologically- and biotechnologically- relevant molecules (including 
polymers [28], peptides [29, 30], nucleic acids [31] and carbohydrates [32, 33]) allows 
the generation of potentially stable and biocompatible dispersions. For example, non-
covalent binding of aromatic molecules by π–π stacking onto the surface of the 
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nanotubes [34] or covalent modification of their polyarenic surface [35] allow efficient 
loading of multiple molecules along the length of the nanotubes.  
We have previously shown that encapsulation of radionuclide into the inner space of 
glycan-functionalized single-walled carbon nanotubes (glyco-X@SWCNT) may be 
achieved by molten filling and then covalent modification, allowing in vivo redirection 
distribution of the associated radioactivity from the thyroid to the lungs.[33] Here, we 
use steam-purified and shortened single-walled carbon nanotubes (SWCNTs) [36] 
filled with both ‘cold’ (NaI) and ‘hot’ (Na125I) cargoes and subsequent functionalization 
with different carbohydrates to explore the basis and role of glycan in this redistribution. 
2. Experimental 
2.1. Purification of SWCNTs 
Chemical vapour deposition (CVD) grown SWCNTs, were provided by Thomas Swan & Co. 
Ltd (Elicarb®). Steam purification was carried out in order to remove the amorphous carbon 
and graphitic shells formed during the synthesis [36]. Steam treatment was simultaneously 
employed to open the SWCNTs ends. For this purpose, 1 g of as-received SWCNTs were 
ground with agate mortar and pestle and then placed inside a tubular furnace. Steam was 
introduced by bubbling argon through hot water. The temperature was raised by 20 °C/min 
till 900 °C, where the SWCNTs remained for 25 h. After cooling at a rate of 10 °C/min down 
to 25 °C, the powder was dispersed in a 6 M HCl solution and refluxed at 110 °C during 6 h 
to remove the iron catalyst exposed after the steam oxidation of the graphitic shells. The 
mixture was cooled, filtered using a 0.2 µm polycarbonate membrane, washed with distilled 
water until neutral pH was reached and dried overnight at 60 °C. After this treatment, 
SWCNTs with a median length of ca. 200 nm are obtained [37]. 
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2.2. Filling of SWCNTs with NaI by molten phase capillary wetting 
Purified and open-ended SWCNTs (100 mg) and NaI (1 g) were ground together and 
loaded into a silica ampoule. The system was evacuated and the ampoule was sealed 
under vacuum. The sample was subsequently annealed at 900 °C and slowly cooled down 
to favour the crystallization of NaI within the hosting SWCNTs. Afterwards, the system was 
air opened and the sample was ground with an agate mortar and pestle. The sample was 
next washed in water, to remove the non-encapsulated NaI, and collected by filtration on 
top of a polycarbonate membrane (0.2 µm Whatman). 
2.3. Synthesis of f-NaI@SWCNTs 
4-(2-(bis(2-tert-butoxycarbonyl-aminoethyl)amino)ethylamino)oxobutanoic acid: To a 
solution of tris(2-aminoethyl)amine (6 mL, 41 mmol, 5 eq.) in ACN (200 mL) at 0 °C was 
added, dropwise, a solution of succinic anhydride (822 mg, 8.2 mmol, 1 eq.) in ACN (100 
mL). The reaction was stirred at r.t. for 2 h, before the solution was poured away and the 
precipitate recovered with MeOH, and finally dried under vacuum to afford 4-(2-(bis(2-
aminoethyl)amino)ethylamino)oxobutanoic acid as a yellow oil (2.0 g, 8 mmol, 98%).  
To a solution of 4-(2-(bis(2-aminoethyl)amino)ethylamino)oxobutanoic acid (343 mg, 1.39 
mmol, 1 eq.) in dioxane (15 mL) was added di-tert-butyl dicarbonate (611 mg, 2.8 mmol, 2 
eq.). The reaction mixture was stirred for 4 h at r.t. The reaction was evaporated, and the 
residue purified by flash column chromatography over silica (DCM:MeOH, 10:0.2 to 10:2), 
to afford the title compound as a white solid (246.8 mg, 0.55 mmol, 40%).  
N-(2,2’-(ethylenedioxy)diethylamino) benzylacetate: To a solution of N-(N-tert-
butoxycarbonyl-(2,2’-(ethylenedioxy)diethylamino)) benzylacetate [38] (1.1056 g, 2.79 
mmol, 1 eq.) in DCM (5.6 mL) was added TFA (2.4 mL). The reaction was stirred at r.t. for 1 
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h, before being evaporated under vacuum to afford the title compound as a yellow oil (1.08 
g, 2.79 mmol, quant.).  
N-(4-(2-(bis(2-tert-butoxycarbonyl-aminoethyl)amino)ethylamino)oxobutanoyl) N-(2,2’-
ethylenedioxy)diethylamino)benzylic acid (1.0):  
(1)  To a solution of 4-(2-(bis(2-tert-butoxycarbonyl-aminoethyl)amino)ethylamino) 
oxobutanoic acid (1.230 g, 2.75 mmol, 1 eq.) in DMF (55 mL), were added HATU 
(2.091 g, 5.5 mmol, 2 eq.), HOBt (743 mg, 5.5 mmol, 2 eq.) and DIPEA (960 µL, 5.5 
mmol, 2 eq.). Finally, N-(2,2’-(ethylenedioxy)diethylamino) benzylacetate (978.8 mg, 
3.3 mmol, 1.2 eq.) was added and the mixture stirred at r.t. for 6 h. The reaction was 
evaporated to a small volume, recovered with DCM (150 mL) and washed with H2O 
(200 mL) and Brine (200 mL). The organic layer was dried over MgSO4 and 
evaporated under vacuum, to afford the title compound as a yellow oil (1.8455 g, 
2.55 mmol, 92%).  
(2) To Pd/C (10 mg, 10 wt. % loading) under hydrogen, was added a solution of N-(4-
(2-(bis(2-tert-butoxycarbonyl-aminoethyl)amino)ethylamino)oxobutanoyl) N-(2,2’-
ethylenedioxy) diethylamino) benzylacetate (386 mg, 0.53 mmol, 1 eq.) in MeOH 
(dry, 3 mL). The reaction mixture was stirred at r.t. for 5 h, filtered over celite and 
evaporated under vacuum. The crude was purified by flash column chromatography 
on silica (DCM:MeOH, 9:1 to 0:1) to afford the title compound as a colourless oil 
(220.4 mg, 0.35 mmol, 66%). 
 
A suspension of NaI@SWCNTs (6 mg) in DMF (dry, 3 mL) was sonicated for 2 min, before 
a solution of N-(4-(2-(bis(2-tert-butoxycarbonyl-aminoethyl)amino)ethylamino)oxobutanoyl) 
N-(2,2’-ethylenedioxy)diethylamino)benzylic acid 1.0 (12.7 mg, 0.02 mmol, 1 eq.) and 2,3,5-
triiodobenzaldehyde [33] (9.6 mg, 0.02 mmol, 1 eq.) in DMF (dry, 1 mL) was added. The 
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reaction was refluxed at 130 °C for 4 days, then cooled to r.t. and filtered. The solid was 
washed with DMF, MeOH and dried under vacuum to afford di-Boc-f-NaI@SWCNTs as a 
black solid (6.8 mg).  
 
A suspension of di-Boc-f-NaI@SWCNTs (12.2 mg) in DCM (dry, 5 mL) was sonicated for 2 
min, before TFA (2.5 mL) was added. The reaction was stirred at r.t. for 24 h, then 
evaporated, recovered with MeOH, filtered and washed with MeOH. The solid obtained was 
dried under vacuum to afford the title compound as a black solid (9.46 mg).  
2.4. Fmoc numbering f-NaI@SWCNTs  
A solution of Fmoc chloride (1 mg, 3.86 µmol, 1 eq.) in DCM (0.5 mL) was added dropwise 
to a suspension of f-NaI@SWCNTs (1 mg) in DCM (0.5 mL) at 0 °C. DIPEA (1.5 µL, 8.61 
µmol, 2.2 eq.) was added and the reaction was stirred at r.t. for 16 h. The reaction mixture 
was centrifuged, the supernatant discarded and the solid recovered with MeOH then filtered 
and washed with MeOH. The solid obtained was dried under vacuum and treated with 
DMSO:DMF:DBU (25:24:1 solution, 1 mL) at r.t. to cleave the Fmoc group. After 2 h, 20 µL 
of the crude were added to 1000 µL of MeOH. The sample was centrifuged and the 
absorbance of the solution measured by UV at 295 nm (A = 0.065698, Ԑ = 10,027 cm-1M-1). 
The functionalization of the nanotubes obtained was 0.34 mmol/g. 
 
2.5 Synthesis of Glycosylated-NaI@SWCNTs 
 
2-acetamido-1-thio-(S-2-imido-2-methoxyethyl)-2-deoxy-β-D-glucopyranoside 1.1: To a 
solution of 2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-(S-cyanomethyl)-β-D-
glucopyranoside [39]  (20 mg, 0.05 mmol, 1 eq.) in MeOH (dry, 1 mL) was added NaOMe 
(25% in MeOH, 12 µL, 0.05 mmol, 1 eq.). The reaction was stirred at r.t. for 16 h before 
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being neutralised with DowexH+. The reaction mixture was filtered and evaporated without 
heating. The product was obtained as a mixture of deprotected (R-SCM) and activated 
sugars (R-IME, 2.80) in ratio 1:0.5 (determined by NMR, 1H, MeOD), and used in the next 
step without further purification.  
2,3,6-O-tri-O-acetyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl]-1-thio-(S-
cyanomethyl)-β-D-glucopyranoside To β-lactose (10 g, 29.2 mmol, 1 eq.) were added Ac2O 
(155 mL, 1636 mmol, 56 eq.) and NaOAc (10 g, 122.6 mmol, 4.2 eq.). The reaction was 
stirred at 140 °C for 5 h, recovered with H2O (200 mL) and extracted with DCM (3 x 200 
mL). The organic layer was washed with NaHCO3 satd. solution (200 mL) and brine (200 
mL), then dried over MgSO4, evaporated and co-evaporated with toluene, to afford 1,2,3,6-
O-tetra-O-acetyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl]-β-D-glucopyranoside 
[40] as a light yellow foam (19.9 g, 29.2 mmol, quant.).  
 
To 1,2,3,6-O-tetra-O-acetyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl]-β-D-
glucopyranoside (14.15 g, 20.85 mmol, 1 eq.) in an ice bath, were added HBr (33% in 
AcOH, 23 mL, 129.27 mmol, 6.2 eq.) and Ac2O (4.2 mL, 43.785 mmol, 2.1 eq.). The 
reaction was stirred for 3 h, recovered with DCM (200 mL) and poured into H2O (200 mL). 
The mixture was stirred with NaHCO3 satd. solution (300 mL), the organic layer separated 
and washed with NaHCO3 satd. solution (3 x 200 mL) and brine (200 mL). The organic 
layer was dried over MgSO4 and evaporated to afford 2,3,6-O-tri-O-acetyl-4-O-[2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl]-1-bromo-α-D-glucopyranoside [41] as a white foam 
(13.27 g, 19 mmol, 91%).  
 
2,3,6-O-tri-O-acetyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl]-1-bromo-α-D-
glucopyranoside (14.58 g, 20.85 mmol, 1 eq.) was mixed with thiourea (3.5 g, 45.87 mmol, 
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2.2 eq.) and dissolved in acetone (50 mL). The reaction was stirred for 3 h at 80 °C, then 
evaporated. The solid was recovered with acetone (60 mL), and Na2S2O5 (10.3 g, 54.21 
mmol, 2.6 eq.), K2CO3 (4 g, 29.19 mmol, 1.4 eq.) and chloroacetonitrile (20 mL, 316.92 
mmol, 15.2 eq.) were added The mixture was stirred at r.t. for 3 h, evaporated and purified 
by flash column chromatography on silica (EtOAc:PE, 1:1) to afford the title compound as a 
white foam (8.7621 g, 12.6 mmol, 63%).  
4-O-[β-D-galactopyranosyl]-1-thio-(S-2-imido-2-methoxyethyl)-β-D-glucopyranoside 1.2: To 
a solution of 2,3,6-O-tri-O-acetyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl]-1-thio-
(S-cyanomethyl)-β-D-glucopyranoside (100 mg, 0.14 mmol, 1 eq.) in MeOH (dry, 1 mL) was 
added NaOMe (25% in MeOH, 33 µL, 0.14 mmol, 1 eq.). The reaction was stirred at r.t. for 
16 h before being neutralised with DowexH+. The reaction mixture was filtered and 
evaporated without heating. The product was obtained as a mixture of deprotected (R-
SCM) and activated sugars (R-IME, 2.87) in ratio 1:0.7 (determined by NMR, 1H, MeOD), 
and used in the next step without further purification.  
GlcNAc-NaI@SWCNTs: A solution of 2-acetamido-1-thio-(S-2-imido-2-methoxyethyl)-2-
deoxy-β-D-glucopyranoside (6.5 mg, 20 µmol, 1 eq.) in MeOH:DMSO (2:1, 1.5 mL) was 
added to a suspension of f-NaI@SWCNTs (1 mg) in DCM (0.5 mL). The reaction was 
stirred at r.t. for 30 min. The reaction mixture was centrifuged, the supernatant discarded 
and the solid recovered with MeOH, filtered and washed with MeOH. The solid obtained 
was dried under vacuum to afford the title compound as a black solid (0.88 mg). EA (C, H, 
N) 67.34, 1.08, 2.98. 
Lac-NaI@SWCNTs: A solution of 4-O-[β-D-galactopyranosyl]-1-thio-(S-2-imido-2-
methoxyethyl)-β-D-glucopyranoside (6.5 mg, 20 µmol, 1 eq.) in MeOH:DMSO (2:1, 1.5 mL) 
was added to a suspension of f-NaI@SWCNTs (1 mg) in DCM (0.5 mL). The reaction was 
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stirred at r.t. for 30 min. The reaction mixture was centrifuged, the supernatant discarded 
and the solid recovered with MeOH, filtered and washed with MeOH. The solid obtained 
was dried under vacuum to afford the title compound as a black solid (0.8 mg). EA (C, H, N) 
67.32 ,1.11, 3.01. 
 
2.6 Synthesis of glycosylated-Na125I@SWCNTs 
Filling of SWCNTs with Na125I: Steam-purified SWCNTs (1 mg) were loaded in a silica 
ampoule with Na125I solution (10-5 M, 100 µL, 20 MBq), dried and sealed under high 
vacuum with an oxygen-propane flame. The ampoule was heated in a furnace up to 900 °C 
using the same ramp described for the cold samples. The sample was recovered from the 
ampoule with H2O (1 mL), sonicated and filtered. Final activity = 9 MBq (1 mg, RCY = 
45%). 
 
f-Na125I@SWCNTs: A suspension of Na125I@SWCNTs (1 mg, 9 MBq) in DMF (dry, 3 mL) 
was sonicated for 2 min, before a solution of N-(4-(2-(bis(2-tert-butoxycarbonyl-
aminoethyl)amino)ethylamino) oxobutanoyl) N-(2,2’-ethylenedioxy)diethylamino)benzylic 
acid (12.7 mg, 0.02 mmol, 1 eq.) and 2,3,5-triiodobenzaldehyde (9.6 mg, 0.02 mmol, 1 eq.) 
in DMF (dry, 1 mL) was added. The reaction was refluxed at 130 °C for 4 days, then cooled 
to r.t. and filtered. The solid was washed with DMF, MeOH and dried under vacuum to 
afford di-Boc-f-Na125I@SWCNTs as a black solid (1 mg, 9 MBq). 
A suspension of di-Boc-f-Na125I@SWCNTs (1 mg, 9 MBq) in DCM (dry, 5 mL) was 
sonicated for 2 min, before TFA (2.5 mL) was added. The reaction was stirred at r.t. for 24 
h, then evaporated, recovered with MeOH, filtered and washed with MeOH. The solid 
obtained was dried under vacuum to afford the title compound f-Na125I@SWCNTs as a 
black solid (1 mg, 9 MBq). 
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GlcNAc-Na125I@SWCNTs: A solution of 2-acetamido-1-thio-(S-2-imido-2-methoxyethyl)-2-
deoxy-β-D-glucopyranoside (6.5 mg, 20 µmol, 1 eq.) in MeOH:DMSO (2:1, 1.5 mL) was 
added to a suspension of f-Na125I@SWCNTs (0.3 mg, 3 MBq) in DCM (0.5 mL). The 
reaction was stirred at r.t. for 30 min. The reaction mixture was centrifuged, the supernatant 
discarded and the solid recovered with MeOH, filtered and washed with MeOH. The solid 
obtained was dried under vacuum to afford the title compound as a black solid (0.3 mg, 3 
MBq). 
Lac-Na125I@SWCNTs: A solution of 4-O-[β-D-galactopyranosyl]-1-thio-(S-2-imido-2-
methoxyethyl)-β-D-glucopyranoside (6.0 mg, 20 µmol, 1 eq.) in MeOH:DMSO (2:1, 1.5 mL) 
was added to a suspension of Na125I@SWCNTs (0.3 mg, 3 MBq) in DCM (0.5 mL). The 
reaction was stirred at r.t. for 30 min. The reaction mixture was centrifuged, the supernatant 
discarded and the solid recovered with MeOH, filtered and washed with MeOH. The solid 
obtained was dried under vacuum to afford the title compound as a black solid (0.3 mg, 3 
MBq). 
For characterization details, namely, TGA, HRTEM, STEM, TLC, NMR mass spectrometry 
and Infrared spectroscopy see Supporting information. 
 
3. Results and discussion 
3.1 Preparation of ‘cold’ glyco-NaI@SWCNTs. 
To prepare the nanotubes for filling they were first treated with steam, followed by an HCl 
(aq) wash, in order to remove graphitic nanoparticles, amorphous carbon and metal 
catalysts that remain as impurities from their generation [36]. This method also results in 
simultaneous shortening of the nanotubes via a process believed to involve oxidation and 
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decarboxylation of more reactive carbon atoms present at their tips [36]. TEM images of 
both as-received and steam-purified SWCNTs are shown in Figure S1; these revealed 
some residual iron-derived nanoparticles (from the preparative catalyst) after steam 
treatment. Sodium iodide (hot or cold) was filled into these carbon nanotubes to generate 
NaI@SWCNTs by adaptation of the protocol developed by Green et al. for the creation of 
KI ‘nanocrystals’ in SWCNTs [5]. Thus, a mixture of steam purified SWCNTs and the metal 
halide was annealed above the melting point of the inorganic salt (m.p.NaI = 661 ºC) inside 
an evacuated silica ampoule. Heating at 900 ºC not only drove encapsulation of salt inside 
the nanotubes, but also induced the closing of their tips [20]. In this way, internal NaI 
crystals were isolated from the outer environment by the formation of carbon 
‘nanocapsules’ [42] (or ‘nanobottles’ [30]). As a result, any residual, external NaI present 
after synthesis was easily removed simply by washing the sample in refluxing water.  
Characterization by high-angle annular dark-field scanning transmission electron 
microscopy (HAADF-STEM) allowed encapsulated salt to be clearly discerned from the 
walls of the nanotubes (Figure 1). Visual inspection allowed filled SWCNTs containing 
heavy atoms (Figure S2, white arrowed) to be readily distinguished from empty (red 
arrowed). This also confirmed that washing with water after filling successfully removed all 
residual salt from the outer surfaces of the CNTs in the sample. Successful encapsulation 
of NaI was also confirmed using high-resolution transmission electron microscopy (HRTEM, 
Figure 1b), allowing observation of even the crystalline lattice of encapsulated NaI. Finally, 
analysis of the sample with energy dispersive X-ray spectroscopy (EDX, Figure 1c) further 





Fig. 1. NaI-filled SWCNTs (NaI@SWCNT). (a) HAADF-STEM; since the intensity of the 
signal scales up to ca the square of the atomic number, the heavier atoms of the guest (Na 
and I) appear as brighter lines along the inner cavities of the nanotubes compared to C 
from their walls; (b) HRTEM image; (c) EDX spectroscopy confirmed the presence of Na 
and I. Fe and Cu signals correspond to those from SWCNT-generation catalyst residuals 




Following successful filling to form NaI@SWCNT, covalent functionalization of the 
sidewalls was achieved under mild conditions via 1,3-dipolar cycloaddition using 
appropriately functionalized azomethine ylids [14, 43, 44] (Scheme 1). The choice of 
ylid also simultaneously allowed introduction of a 2,3,5-triiodophenyl motif as a 
‘marker’ or ‘tagging’ motif,[45] suitable for the ready detection of successful 
functionalization using electron microscopy. To allow more ready diversification of 
glycan, a prior strategy devised by Hong et al. [33] was altered through first introducing 
a Boc-protected bis-amine branched linker moiety 1.0 to the CNT (Scheme 1), 
followed by deprotection using TFA to form a functionalized divergent intermediate, f-
NaI@SWCNT. Fmoc-numbering[33] was employed to quantify the loading of the 
primary amine groups thus introduced and hence the degree of functionalization at 
0.34 mmol/g. 
Intermediate f-NaI@SWCNT was then subsequently glycoconjugated with appropriate 
amine-reactive glycan-IME imidate reagents,[46, 47] GlcNAc-IME 1.1 or Lac-IME 1.2 
to introduce GlcNAc or lactose (Galβ1,4–Glc) to the linkers attached to surface of the 





Scheme 1. Functionalization of NaI@SWCNTs with biantennary linker reagent 1.0 and 
subsequent glycosylation. Reagents and conditions: a) DMF, 130 °C, 4 days; b) DCM, 




Fig. 2. HAADF-STEM images of (a) as-filled sample and (b) after GlcNAc 
functionalization to form [GlcNAc]2-NaI@SWCNT. The respective HAADF intensity 
profiles along the white dashed boxes demonstrate that the intensity in the bundle area 
is higher for the [GlcNAc]2-NaI@SWCNT, in agreement with the presence of iodide (Z 




HAADF-STEM imaging of the samples after GlcNAc functionalization Figure 2 
revealed a higher intensity in the bundle area when compared to the as-filled 
NaI@SWCNTs, due to the presence of the 2,3,5-triiodophenyl ‘marker’ combined into 
the linker moiety, thereby confirming successful covalent functionalization. The 
introduction of the linker to the surface of NaI@SWCNTs in f-NaI@SWCNTs, 
[GlcNAc]2-NaI@SWCNT and [Lac]2-NaI@SWCNT was also confirmed by TGA (Figure 
3). Unlike the NaI@SWCNTs whose combustion starts ~ 400 ºC, weight loss at lower 
temperatures even down to ~ 200 ºC was observed that can be attributed to the 
combustion of the organic fraction attached to the nanotubes. GlcNAc and Lac 
functionalized SWCNTs showed higher thermal stabilities than the linker-functionalized 
SWCNT f-NaI@SWCNTs. During functionalization inorganic materials are employed 
(e.g. MgSO4) that appear to remain in the functionalized samples and contribute to an 
unexpected increase in the amount of inorganic residue collected after the TGA for 
those samples that have been through these processes (SI Figure S4). Successful 
glycoconjugation was further confirmed by elemental combustion analyses (see 





Fig. 3. TGA analyses of NaI filled SWCNTs (NaI@SWCNTs), and after being 
externally functionalized (f-NaI@SWCNTs) and glycosylated ([GlcNAc]2-




3.2 Preparation of ‘hot’ glyco-Na125I@SWCNTs. 
One mode in which glycosylated-‘nanocapsules/bottle’ might be exploited is in the 
highly controlled and localized delivery of radioactivity. This also potentially allows 
quantification of biodistribution and even direct imaging of this delivery. To test the 
potential of our glycosylated nanotubes in vivo we created ‘hot nanobottle’ 
isotopologue variants in which we replaced ‘cold’ NaI with ‘hot’, radioactive Na125I.  
Gamma emission from 125I allows sensitive quantification and hence whole body 
distribution of constructs through ‘gamma counting’ of samples. Empty SWCNTs 
underwent an adapted molten phase filling process: SWCNTs and an aqueous solution 
of the radioactive salt were placed in a silica ampoule and heated to remove water. 
The ampoule was then sealed under vacuum and annealed following the protocol 
employed for ‘cold’ NaI. The functionalization and glycoconjugation process was 
carried out in an essentially analogous manner to that used for non-radioactive 
samples to generate ‘hot’ f-Na125I@SWCNTs (0.3 mg, 3 MBq), ‘hot’ [GlcNAc]2-
Na125I@SWCNTs (0.3 mg, 3 MBq) and ‘hot’ [Lac]2-Na125I@SWCNTs (0.3 mg, 3 MBq).  
 
3.3 Biodistribution analyses of ‘hot’ and ‘cold’ glyco-NaI@SWCNTs. 
Previous studies performed on the robustness of radionuclide-filled nanotubes in 
biological environments have shown a strong correlation between radioactivity and 
nanotube distribution, suggesting negligible leakage of radionuclide salts [33, 48]. This 
is particularly the case when using radio-iodide as ‘cargo’; free iodide is readily taken 
up by the thyroid leading to sensitive observation – no such free iodide was detected 
in these prior studies. We used this correlation to quantify the distribution of nanotubes 
via gamma emission from the encapsulated Na125I cargo. ‘Hot’ glyco-Na125I@SWCNTs 
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were injected in CD-1 male mice (0.1 mg/100 µL) and biodistribution after 1 hour 
determined from gamma radiation levels in different organs (lungs, liver, spleen, brain, 
gut, kidneys, muscle and heart) ex vivo (Figure 4).  
Two variants of mammalian glycans were chosen to test influence upon biodistribution. 
Both have putative endogenous receptors in mammals with different in vivo distribution. 
GlcNAc was used in our prior study in which functionalized NaI@SWCNTs containing 
radioactive iodide was successfully delivered into the lungs [33] and was again used 
here in [GlcNAc]2-Na125I@SWCNT. Galactosyl-terminated, Lac, is considered to be a 
‘liver-targeting’ agent due to its interaction as a ligand with the asialoglycoprotein 
receptors expressed on hepatocytes [49] and was selected in this study as the second 
glycan and used in [Lac]2-Na125I@SWCNT. The distribution profile determined from 
both [GlcNAc]2-Na125I@SWCNT and [Lac]2-Na125I@SWCNT (Figure 4), however, 
showed no significant differences in biodistribution with essentially complete 
accumulation of the radioactivity in the lungs for both samples after tail-vein injection. 
This negligible influence of glycan was further confirmed by the identical in vivo 
behaviour of non-glycosylated precursor f-Na125I@SWCNT (Figure 4).  
Next, in order to test whether biodistribution could be attributed to dominant, inherent 
physiological properties of the nanotubes, we attempted to assess the effect of an 
alternative injection site via intra-aortic injection that necessitated preferential use of 
‘cold’ glyco-SWCNTs and quantification instead by ICP-MS of tissue-derived samples. 
These analyses calibrated by internal standard revealed a lower method detection limit 
for iodide in tissue under these conditions of ~25 ng/g.tissue; iodide was also 
successfully observed in samples from animals treated with glyco-NaI@SWCNT at 
levels of up to 126 ng/g.tissue. However, although iodide levels were found in certain 
organs (liver, lung and spleen) of up to 60 ng/g.tissue above those found in control, 
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untreated animals, these should be treated as only suggestive qualitative indications – 
statistical analyses do not allow support of any quantitative significance. Thus, whilst 
these may be indicative of broader organ distribution caused by an alternative injection 
site, the use of ‘cold iodide’ tracking of filled, functionalized NaI@SWCN in vivo by 
ICP-MS analysis of tissues appears to lack the sensitivity required for unambiguous 
biodistribution analysis. 
Together these data suggested that, at the loadings of surface functionalization used 
here, glycosylation serves only to aid dispersibility rather than providing any form of 
‘targeting’. Instead, once dispersed, glyco-SWCNTs may deliver their ‘cargo’ via 
various physiological mechanisms that may include recruitment at the first capillary 





Fig. 4. Biodistribution of amine-functionalized and glycosylated Na125I@SWCNTs. Organs 
of CD-1 mice were harvested 1 h after tail-vein injection of amine-functionalized (f-
Na125I@SWCNTs) and glycosylated nanotubes (GlcNAc-Na125I@SWCNTs; Lac-
Na125I@SWCNTs). The distribution of the samples in the tissues was determined by ɣ-





Functionalized and glycosylated nanotubes can act as ‘nanocapsules’ or ‘nanobottles’ 
to redirect the accumulation of inorganic radionuclide ‘cargo’ concealed in their inner 
void (here iodide) from a natural physiological target (here thyroid) [50] to alternative 
targets. At the functionalization loadings used here, different glycosylation patterns on 
these glyco-‘nanobottle’ constructs did not modulate in vivo distribution profiles. 
Instead, these appear to only aid dispersibility; these dispersed carbon nanotubes then 
appear to accumulate in a manner that is primarily determined by their physical 
properties within physiology (e.g. recruitment at the first capillary bed that they 
encounter) in a manner that is more likely to be determined by administration site than 
by any specific ligand-receptor targeting interaction at these lower loading of surface 
ligands on filled SWCNTs. It should be noted that overly high rates of injection can 
affect distribution. We injected 100µL of suspension over a 10-second period in which 
the heart would normally pump ~2.5-3.0 mL of blood. The mouse has a blood volume 
of ~1.5mL. Thus our injection was less than 4% volume at a rate well below suggested 
typical maximum of, e.g. 50 µL/s.{Diehl, 2001 #79} 
These ‘nanocapsules/bottles’ may represent a useful, sealed ‘source of radiation’. If 
this could be combined with the benefits of a deliverable system, this could create a 
potentially suitable form of ‘nanobrachytherapy’. Given the seemingly dominant control 
of physical properties rather than biochemical properties upon distribution observed 
here, we speculate that future manipulation of not only surface functionalization (e.g. 
at higher levels or with different types) but even via changes to carbon nanostructure 
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Supplementary Data (Appendix A) 
In vivo behaviour of glyco-NaI@SWCNT 
‘nanobottles’ 
Sonia De Munari,a Stefania Sandoval,b Elzbieta Pach,c Belén Ballesteros,c Gerard 
Tobias,b* Daniel C. Anthonyd* and Benjamin G. Davisa* 
 
S1. GENERAL CONSIDERATIONS AND SYNTHESIS  
- Microscopic characterization 
The successful filling of SWCNTs was confirmed recording HRTEM images, high-
angle annular dark field (HAADF) images in scanning transmission electron 
microscopy (STEM) mode and energy dispersive X-ray spectroscopy (EDX). Images 
and EDX data were acquired at 200 kV on a FEI Tecnai G2 F20 HR(S)TEM 
equipped with an EDAX super ultra-thin window (SUTW) X-ray detector. Samples 
were prepared dispersing a small amount in hexane and sonicating during 15 min. 
Afterwards, the solution was placed dropwise onto lacey carbon coated Cu support 
grids. 
- Thermogravimetric analysis (TGA) 
TGA was performed on a Netzsch STA 449 F1 Jupiter® instrument. Analyses were 
performed under flowing synthetic air at temperatures ranged between 25 ºC and 
900 ºC using a heating rate of 10 ºC.min-1. 
 
- Nuclear Magnetic Resonance and Mass spectrometry 
Proton nuclear resonance magnetic (1H NMR) spectra, 13C NMR, correlation 
spectroscopy (COSY) and heteronuclear single-quantum correlation spectroscopy 
(HSQC), were recorded on Bruker AV500, Bruker AV400 and Bruker AV250 (500, 
S2	
	
400, 250 MHz) spectrometers. All chemical shifts are quoted on the δ scale in ppm, 
using residual solvents as the internal standard (1H NMR: CDCl3 = 7.26, DMSO-d6 = 
2.50, MeOD = 3.31, D2O = 4.79; 13C NMR: CDCl3 = 77.16, DMSO-d6 = 39.52, MeOD 
= 49.00). Coupling constants (J) are reported in Hz with the following splitting 
abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = 
doublet of doublets, dt = doublet of triplets, qd = quartet of doublets, ddd = doublet of 
doublet of doublets, br = broad. All chemical shifts were assigned using COSY and 
HSQC spectra. 
Low resolution mass spectra (LRMS) and high resolution MS (HRMS) were recorded 
on a Waters Micromass LCT Premier TOF spectrometer using electrospray 
ionisation (ESI). 
Liquid Chromatography-Mass Spectrometry (LC-MS) was performed on a Waters 
LCT Premier XE (ESI-TOF-MS) coupled to a Waters 1525 Micro HPLC pump 2777 
autosampler, using a Merk Chromolith RP-18 2 x 5 mm guard column. Water 
containing 0.1% formic acid by volume (solvent A) and acetonitrile (solvent B), were 
used as the mobile phase at a flow rate of 0.4 mL/min. The gradient was 
programmed as follows: 
- 0 min 95% A 5% B  0.4 mL/min 
- 1 min 95% A 5% B  0.4 mL/min 
- 5 min 0% A 100% B 0.4 mL/min 
- 8 min 0% A 100% B 1 mL/min 
- 8.1 min 95% A 5% B  1 mL/min 
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The electrospray source was operated with a capillary voltage of 3 kV and a cone 
voltage of 100 V. Nitrogen was used as the nebulizer and desolvation gas, at a total 
flow of 300 L/hr. 
- General Synthetic Methods 
Thin layer chromatography (TLC) was carried out using Merck aluminium backed 
sheets coated with 60 F254 silica gel. Visualisation of the silica plates was achieved 
using a UV lamp (λmax = 254 nm), and/or ammonium molybdate (5% in 2 M H2SO4), 
ninhydrin (1.5 g ninhydrin, 5 mL acetic acid, 500 mL 95% ethanol) or sulfuric acid (45 
mL methanol, 45 mL water, 3 mL sulfuric acid) solutions. Flash column 
chromatography was carried out using Geduran Si 60 (40-63 µm) Merk. Mobile 
phases are reported as ratio volume:volume. 
All solvents were used as supplied (analytical or HPLC grade), without prior 
purification. PE refers to the fraction of petroleum ether boiling in the range of 40-60 
°C. All reactions requiring anhydrous conditions we performed inflame-dried flasks, 
with activated molecular sieves, dried solvents and argon atmosphere. Brine refers 
to a saturated aqueous solution of sodium chloride. Anhydrous magnesium sulphate 
(MgSO4) was used as drying agent after reaction work-up. Deionised water was 
used for chemical reactions and protein manipulations. Reagents were purchased 
from Sigma-Aldrich and used as supplied. 
Nanotubes were purified and filled in a Carbolite horizontal single zone tube furnace, 
model MTF 12/38/250 with PID controller type 3216P1. Radioactive samples were 
counted on a Autogamma counter (Packard Instrument Co., Downers Grove, IL). 
Elemental analyses were run by Stephen Boyer (Science Centre, London 
Metropolitan University, 29 Hornsey Road, London N7 7DD). 
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Animals were purchased from Charles River (UK); animal experiments were 
performed by Sonia De Munari (PIL: IC7F41F8D) and Daniel Anthony under project 
license 30/3076 with the UK Home Office and local ethical approval. 
Room temperature was defined as 21 °C. 
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- Synthesis of f-NaI@SWCNTs  
4-(2-(bis(2-aminoethyl)amino)ethylamino)oxobutanoic acid :TLC Rf = 0.1 (WIPE, 
1:2:2); 1H NMR (MeOD, 400 MHz) δ 3.30 (t, J = 4.6 Hz, 2 H, CH2NH) , 2.86 (t, J = 
4.6 Hz, 4 H, 2 x CH2NH2), 2.64-2.59 (t, J = 4.5 Hz, 6 H, 3 x CH2N), 2.45 (br, 4 H, 
COCH2CH2CO); 13C NMR (MeOD, 101 MHz) δ 175.10, 179.93 (2 x CO), 54.25, 
55.12 (3 x CH2N), 38.28, 38.53 (CH2NH, 2 x CH2NH2), 32.75, 33.35 
(COCH2CH2CO); LRMS (ESI+) m/z = 247.31 [M+H]; HRMS (ESI+) found 247.1763 
[M+H], C10H23N4O3 requires 247.1765; IR (ATR) 3271.00 (OH), 1703.87 (COOH), 
1697.90 (CONH). 
4-(2-(bis(2-tert-butoxycarbonyl-aminoethyl)amino)ethylamino)oxobutanoic acid: TLC 
Rf = 0.85 (DCM:MeOH, 10:1); 1H NMR (CDCl3, 250 MHz) δ 3.27 (br, 2 H, 
CH2NHCOCH2), 3.13 (br, 4 H, 2 x CH2NHCOO) , 2.52 (br, 10 H, 3 x CH2N, 
COCH2CH2CO), 1.41 (s, 18 H, 2 x tBu); 13C NMR (CDCl3, 126 MHz) δ 172.69, 
157.98, (2 x COCH2), 156.63 (2 x COOC), 81.28 (C(CH3)3), 79.46, 79.22 (3 x CH2N), 
39.10, 36.86 (3 x CH2NH), 31.66, 31.02 (COCH2CH2CO), 28.40 (C(CH3)3); LRMS 
(ESI+) m/z = 447.55 [M+H]; HRMS (ESI+) found 447.2819 [M+H], C20H39N4O7 
requires 447.2813; IR (ATR) 3277.19 (OH), 1708.15 (COOH), 1699.62 (CONH), 
1692.96 (COOC); m.p. = 58-61 °C. 
 
N-(2,2’-(ethylenedioxy)diethylamino) benzylacetate: TLC Rf = 0.0 (EtOAc, 100%); 1H 
NMR (CDCl3, 500 MHz) δ 7.35-7.24 (br, 5 H, CH-Ar), 5.15 (br, 2 H, CH2Ph), 3.93 (br, 
2 H, NHCH2CO), 3.72 (br, 2 H, OCH2CH2NH2), 3.66 (br, 2 H, CH2CH2NH), 3.59 (br, 4 
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H, OCH2CH2O), 3.31 (br, 2 H, OCH2CH2NH), 3.22 (br, 2 H, OCH2CH2NH2); 13C NMR 
(CDCl3, 126 MHz) δ 166.16 (CO), 133.83 (C-Ar), 118.77, 116.48, 114.19, 111.91 (5 
x CH-Ar), 69.73, 69.85 (OCH2CH2O), 68.78 (COOCH2Ar), 64.99, 65.73 (2 x 
OCH2CH2N), 47.89 (NHCH2CO), 47.76 (CH2CH2NH), 40.10 (CH2NH2); LRMS (ESI+) 
m/z = 297.37 [M+H]; HRMS (ESI+) found 297.1811 [M+H], C15H25N2O4 requires 





(2,2’-ethylenedioxy)diethylamino)benzylic acid: (1) TLC Rf = 0.55 (DCM:MeOH, 9:1); 
1H NMR (DMSO-d6, 400 MHz) δ 7.86 (s, 1 H, NH), 7.46-7.31 (br, 5 H, CH-Ar), 6.79 
(s, 1 H, NH), 5.23 (s, 2 H, CH2Ph), 4.02 (s, 2 H, COCH2NH), 3.73-3.64 (t, J = 4.6 Hz, 
2 H, OCH2CH2NHCO), 3.53 (dt, J = 7.9, 4.8 Hz, 6 H, OCH2CH2O, OCH2CH2NHCH2), 
3.38 (t, J = 6.0 Hz, 2 H, OCH2CH2NHCH2), 3.25-3.07 (br, 6 H, COCH2CH2CO, 
NCH2CH2NHCOCH2), 3.02 (t, J = 4.6 Hz, 2 H, NCH2CH2NHCOCH2), 2.60 (t, J = 4.6 
Hz, 4 H, NCH2CH2NHCOO), 2.31 (br, 4 H, 2 x CH2NHCOO), 1.37 (s, 18 H, 2 x tBu); 
13C NMR (DMSO-d6, 101 MHz) δ 171.98 (COCH2CH2CO), 167.62 (CH2COO), 
156.15 (2 x NHCOO), 135.69 (C-Ar), 128.95, 128.85, 128.72 (5 x CH-Ar), 78.22 
(C(CH3)3), 70.03 (OCH2CH2O), 69.82 (OCH2CH2NHCH2), 69.53 (OCH2CH2NHCH2), 
67.25 (CH2Ph), 66.44 (OCH2CH2NHCOCH2), 53.86 (NCH2CH2NHCOO), 47.69 
(NHCH2CO), 46.87 (NCH2CH2NHCOCH2), 38.94 (COCH2CH2CO), 37.94 
(NCH2CH2NHCOCH2), 31.06 (NCH2CH2NHCOO), 28.67 (C(CH3)3); LRMS (ESI+) 
m/z = 725.89 [M+H]; HRMS (ESI+) found 725.4439 [M+H], C35H61N6O10 requires 
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725.4444; IR (ATR) 3307.05 (NH), 2975.23 (CH), 1693.88 (CONH), 1650.52 
(COCH2Ph), 719.16 (arom).  
(2) TLC Rf = 0.0 (DCM:MeOH, 8:2); 1H NMR (DMSO-d6, 400 MHz) δ 7.98 (d, J = 5.8 
Hz, 1 H, NH), 6.85 (s, 1 H, NH), 3.80-3.62 (t, J = 4.6 Hz, 4 H, OCH2CH2NHCOCH2, 
OCH2CH2NHCH2), 3.60-3.46 (br, 6 H, OCH2CH2O, OCH2CH2NHCH2), 3.39 (t, J = 
5.8 Hz, 2 H, OCH2CH2NHCOCH2), 3.19 (t, J = 4.6 Hz, 4 H, COCH2CH2CO), 3.15-
3.09 (t, J = 4.6 Hz, 2 H, NHCH2COOH), 3.06 (t, J = 4.6 Hz, 4 H, 
NCH2CH2NHCOCH2), 2.72 (t, J = 4.6 Hz, 4 H, 2 x NCH2CH2NHCOO), 2.31 (t, J = 4.6 
Hz, 4 H, 2 x NCH2CH2NHCOO), 1.37 (s, 18 H, 2 x tBu); 13C NMR (DMSO-d6, 101 
MHz) δ 180.63 (COOH), 172.15, 171.99 (2 x COCH2), 156.15 (2 x NHCOO), 78.33 
(C(CH3)3), 72.82 (OCH2CH2O), 69.83 (OCH2CH2NHCH2), 69.56 (OCH2CH2NHCH2), 
66.17 (OCH2CH2NHCOCH2), 53.34 (NCH2CH2NHCOO), 47.83 (NHCH2COOH), 
46.44 (NCH2CH2NHCOCH2), 38.92 (COCH2CH2CO), 36.22 (NCH2CH2NHCOCH2), 
31.08 (NCH2CH2NHCOO), 28.67 (C(CH3)3); LRMS (ESI-) m/z = 633.76 [M-H]; HRMS 
(ESI-) found 633.3833 [M-H], C28H53N6O10 requires 633.3829; IR (ATR) 3342.83 





- – Synthesis of Glycosylated-NaI@SWCNTs 
2-acetamido-1-thio-(S-2-imido-2-methoxyethyl)-2-deoxy-β-D-glucopyranoside: TLC 
Rf = 0.0 (DCM:MeOH, 10:1); 1H NMR (D2O, 500 MHz) δ 4.71 (d, J = 9.3 Hz, 1 H, H-
1), 3.85 (dd, J = 12.4, 2.0 Hz, 1 H, H-6a), 3.72 (t, J = 10.1 Hz, 1 H, H-2), 3.67 (dd, J 
= 12.4, 5.4 Hz, 1 H, H-6b), 3.56-3.47 (t, J = 10.1 Hz, 1 H, H-3), 3.46-3.34 (br, 4 H, 
CH2CNH, H-5, H-4), 3.26 (s, 3 H, OMe), 1.95 (s, 3 H, Ac); 13C NMR (D2O, 126 MHz) 
δ 174.66 (CO),118.43 (CN), 83.80 (C-1), 80.29 (C-5), 75.08 (C-3), 69.99 (C-4), 
60.92, 60.89 (C-6, CH2CNH), 54.34 (C-2), 48.83 (OMe), 22.07 (Ac). 
1,2,3,6-O-tetra-O-acetyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl]-β-D-
glucopyranoside TLC Rf = 0.2 (PE:EtOAc, 1:1); 1H NMR (CDCl3, 400 MHz) δ 6.23 (d, 
J = 3.7 Hz, 0.3 H, H-1eq), 5.65 (d, J = 8.3 Hz, 0.7 H, H-1ax), 5.48-5.41 (t, J = 9.2 Hz, 
0.3 H, H-3α), 5.34 (t, J = 3.2 Hz, 1 H, H-4’), 5.23 (t, J = 9.2 Hz, 0.7 H, H-3β), 5.14 (t, 
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J = 9.5 Hz, 1 H, H-4), 4.91 (dd, J = 10.4, 7.9 Hz, 1 H, H-2’), 4.89 (dd, J = 10.0, 4.0 
Hz, 1 H, H-2), 4.51 (ddd, J = 9.9, 5.0, 1.9 Hz, 1 H, H-5), 4.38 (t, J = 6.8 Hz, 1 H, H-
5’), 4.17 (dd, J = 12.1, 1.9 Hz, 1 H, H-6a), 4.02 (dd, J = 12.1, 1.9 Hz, 1 H, H-6’a), 
3.92 (dd, J = 12.1, 1.9 Hz, 1 H, H-6b), 3.70 (dd, J = 12.1, 1.9 Hz, 1 H, H-6’b), 2.21, 
2.14, 2.10, 2.08, 2.05, 2.03, 2.01, 1.95 (8 x s, 8 x 3 H, 8 x OAc); 13C NMR (CDCl3, 
101 MHz) δ 170.76, 170.72, 170.54, 170.38, 170.27, 170.11, 169.84, 168.52 (8 x 
CO), 101.37 (C-1’), 87.22 (C-1), 74.33 (C-4), 72.35 (C-5), 71.52 (C-3’), 70.34 (C-5’), 
70.11 (C-2), 69.34 (C-3), 69.12 (C-2’), 67.32 (C-4’), 60.92 (C-6’), 60.34 (C-6), 20.97, 
20.88, 20.76, 20.71, 20.69, 20.65, 20.53, 20.12 (8 x Ac); LRMS (ESI+) m/z = 679 
[M+H]; ][ 20Dα  = + 32.9 (c = 1, CHCl3), + 30.2 (c = 1, CHCl3); [1] IR (ATR) 1744 (CO); 
m.p. = 131-134 °C, lit 135 °C.[1] 
2,3,6-O-tri-O-acetyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl]-1-bromo-α-D-
glucopyranoside: TLC Rf = 0.3 (PE:EtOAc, 1:1); 1H NMR (CDCl3, 400 MHz) δ 6.50 
(d, J = 4.0 Hz, 1 H, H-1), 5.52 (t, J = 9.6 Hz, 1 H, H-3), 5.33 (d, J = 2.9 Hz, 1 H, H-4’), 
5.10 (dd, J = 10.4, 7.9 Hz, 1 H, H-2’), 4.93 (dd, J = 10.4, 3.4 Hz, 1 H, H-3’), 4.73 (dd, 
J = 10.0, 4.0 Hz, 1 H, H-2), 4.49 (d, J = 7.9 Hz, 2 H, H-1’, H-6a), 4.29 (d, J = 7.9 Hz, 
2 H, H-1’, H-6b), 3.97 (dd, J = 12.1, 1.9 Hz, 2 H, H-6’), 3.97 (ddd, J = 9.9, 5.0, 1.9 
Hz, 1 H, H-5), 3.93 (t, J = 6.8 Hz, 1 H, H-5’), 3.76 (t, J = 9.5 Hz, 1 H, H-4), 2.13, 2.11, 
2.07, 2.04, 2.04, 2.03, 1.94 (7 x s, 7 x 3 H, 7 x OAc); 13C NMR (CDCl3, 101 MHz) δ 
170.37, 170.20, 170.17, 170.10, 170.00, 169.26, 168.98 (7 x CO), 100.83 (C-1’), 
86.43 (C-1), 74.98 (C-4), 72.99 (C-5), 71.00 (C-3’), 70.85 (C-5’), 70.78 (C-2), 69.59 
(C-3), 69.01 (C-2’), 66.62 (C-4’), 61.06 (C-6’), 60.90 (C-6), 20.84, 20.81, 20.74, 
20.69, 20.68, 20.858, 20.53 (7 x Ac); LRMS (ESI+) m/z = 700 [M+H]; ][ 20Dα  = - 103.1 
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(c = 1, CHCl3), lit - 102.0 (c = 1, CHCl3) [2]; IR (ATR) 1743 (CO); m.p. = 128-131 °C, 
lit 135 °C.[2] 
2,3,6-O-tri-O-acetyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl]-1-thio-(S-
cyanomethyl)-β-D-glucopyranoside : TLC Rf = 0.25 (PE:EtOAc, 1:1); 1H NMR 
(CDCl3, 400 MHz) δ 5.34 (d, J = 2.6 Hz, 1 H, H-4’), 5.24 (t, J = 9.2 Hz, 1 H, H-3), 
5.10 (dd, J = 10.4, 7.9 Hz, 1 H, H-2’), 5.02 (dd, J = 10.0, 4.0 Hz, 1 H, H-2), 4.88 (dd, 
J = 10.4, 3.4 Hz, 1 H, H-3’), 4.68 (d, J = 10.0 Hz, 1 H, H-1), 4.54 (dd, J = 12.1, 1.9 
Hz, 1 H, H-6a), 4.48 (d, J = 7.9 Hz, 1 H, H-1’), 4.19 (dd, J = 12.1, 1.9 Hz, 1 H, H-6b), 
4.02 (dd, J = 12.1, 1.9 Hz, 2 H, H-6’), 3.87 (t, J = 6.8 Hz, 1 H, H-5’), 3.82 (t, J = 9.5 
Hz, 1 H, H-4), 3.68 (ddd, J = 9.9, 5.0, 1.9 Hz, 1 H, H-5), 3.58 (d, J = 17.0 Hz, 1 H, 
CH2aCN), 3.29 (d, J = 17.0 Hz, 1 H, CH2bCN), 2.14, 2.12, 2.09, 2.06, 2.06, 2.04, 
1.95 (7 x s, 7 x 3 H, 7 x OAc); 13C NMR (CDCl3, 101 MHz) δ 170.38, 170.16, 170.10, 
169.81, 169.57, 169.32, 169.03 (7 x CO), 115.74 (CN), 101.06 (C-1’), 81.48 (C-1), 
75.79 (C-5), 73.25 (C-4), 70.94 (C-3), 70.78 (C-5’), 69.89, 69.87 (C-3’, C-2), 69.04 
(C-2’), 66.61 (C-4’), 61.63 (C-6’), 60.83 (C-6), 20.87, 20.81, 20.76, 20.71, 20.68, 
20.65, 20.54 (7 x OAc), 14.48 (CH2CN); LRMS (ESI+) m/z = 692 [M+H]; HRMS 
(ESI+) found 692.1887 [M+H], C28H38NO17S requires 692.1855; ][ 20Dα  = + 34.1 (c = 1, 
CHCl3); IR (ATR) 22141 (CN), 1743 (CO); m.p. = 180-185 °C. 
4-O-[β-D-galactopyranosyl]-1-thio-(S-2-imido-2-methoxyethyl)-β-D-glucopyranoside: 
TLC Rf = 0.0 (DCM:MeOH, 10:1). 1H NMR (D2O, 500 MHz) δ 4.51 (d, J = 9.9 Hz, 1 
H, H-1), 4.37 (d, J = 7.8 Hz, 1 H, H-1’), 3.87-3.82 (br, 2 H, H-6a, H-4’), 3.70 (ddd, J = 
11.6, 8.8, 3.9 Hz, 4 H, H-6’, H-6b, CH2aCNH), 3.66-3.61 (br, 3 H, CH2bCNH, H-3, H-
5), 3.61-3.55 (br, 3 H, H-5’, H-4, H-3’), 3.48-3.44 (br, 1 H, H-2’), 3.36-3.30 (br, 1 H, 
H-2), 3.26 (s, 3 H, OMe); 13C NMR (D2O, 126 MHz) δ 175.53 (CNH), 118.56 (CN), 
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102.81 (C-1’), 84.87 (C-1), 78.68 (C-3), 77.82 (C-3’), 77.75, 75.61, 75.32, 72.47 (C-
4, C-4’, C-5, C-5’), 71.83 (C-2’), 70.91 (C-2), 68.52 (CH2CNH), 61.01 (C-6), 59.98 (C-
6’), 48.82 (OMe). 
- –  Elemental Analysis 
f-NaI@SWCNTs: (C, H, N) 65.66, 1.13, 2.93. 




Figure S1. TEM images of bundles of (a) as-received and (b) steam purified 
SWCNTs. Residual Fe particles are visible as black dots. 
 
Figure S2. (a) HRTEM image of bundles of steam-purified SWCNTs filled with NaI 
via molten-phase capillary wetting through heating treatment up to 900 ºC. (b) 
HAADF-STEM image showing the contrast between the heavy atoms of the salt and 
C atoms. As a guide to the eye, white arrows point to filled SWCNTs and red arrows 
to empty SWCNTs. The visible small dots were already present in empty nanotubes 
and, correspond to residues from the iron-based catalyst used to generate SWNTs 




Figure S3. Additional HAADF-STEM images showing that a higher intensity in the 
bundle area for the GlcNAc functionalized NaI@SWCNTs (b, d) as compared to the 





Figure S4. EDX analyses of samples (a) f-NaI@SWCNT, (b) [Lac]2-NaI@SWCNT 
and (c) [GlcNAc]2-NaI@SWCNT showing that some inorganic materials used during 
functionalization reactions and work up are retained in samples (elements in black: 
attributed to NaI filled carbon nanotubes; elements in red: retained due to the 




S2. BIODISTRIBUTION STUDIES 
 
–   Gamma counting 
 
CD-1 male mice (20-25 g body weight) were injected i.v. with ~0.1 mg (~ 1 MBq) of 
Glycosylated-Na125I@SWCNTs in 100 µL of saline solution (0.9% NaCl in H2O), 
under anaesthesia by isoflurane. The animals were left to recover. After 1 h mice 
were killed by CO2 asphyxiation. Sections of liver (Li), lungs (Lu), heart (H), spleen 
(S), kidneys (K), gut (G), muscles (M1 from hind leg and M2 from front leg) and brain 
(B) were harvested for ex vivo gamma counting. All were run in triplicate. 
 
Table S1. Activity measured by ɣ counter of organs harvested from CD-1 mice after 
injection of GlcNAc-Na125I@SWCNTs and Lac-Na125I@SWCNTs. The values are 
expressed as percentage of the injected dose per gram of tissue (%ID/g). 
Organ GlcNAc-Na125I@SWCNTs Lac-Na125I@SWCNTs 
liver 2 2 
lungs 85 84 
kidneys 2 2 
spleen 3 2 
gut 2 2 
muscle 1 2 2 
muscle 2 1 2 
heart 1 2 




Samples were generated in an essentially similar manner as for gamma counter and 
iodine concentration measured using a Thermo Finnigan Element 2 ICP-MS (by the 
ICP-MS service at Oxford Earth Sciences). Calibrations were obtained using external 
standards (a series of standards of known iodine concentrations were prepared and 
analysed to gain a linear calibration linear, prior to the measurement of samples, r2 
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>0.999); the required serials dilutions were made from a 1000ppm iodide standard- 
bought from High Purity Standards Ltd. As external quality control, an external 
standard was diluted and measured from a different 1000ppm iodide standard, also 
purchased from High Purity Standards. As a mode of internal standardization, all 
blanks, standards and samples were also spiked with 1ng/g Te, so that any general 
instrument drift could be normalised. Samples, blanks, standards and QC were 
diluted using a 2%HNO3 that was adjusted to pH 9 with an addition of 3%NH4OH 
reagent. All data results was measured as elemental concentrations and corrected 
for dilution during sample preparation; they were measured from m/z 127. The 
instrument detection limit was determined to be 12.9 pg/g. The method detection 
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